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DNA replication ensures accurate duplication 
of the original genetic information present in a cell in 
order for it to be properly transmitted to daughter cells. 
However, replication can be perturbed, for instance in 
rapidly dividing cancer cells, in a process referred to as 
replication stress (RS). Checkpoint kinase 1 (CHK1) is an 
essential component of the ATR-dependent DNA damage-
response pathway that protect cells from RS by preventing 
replication fork collapse and activating homologous 
DNA repair. The ATR-CHK1 pathway is triggered upon 
exposure of single-stranded DNA that arises with the 
stalling of replication forks [1], and it is required to reset 
proper origin firing, and to promote fork stability and 
checkpoint activation, delaying mitosis until replication is 
completed and thereby avoiding mitotic catastrophe [2]. 
Whereas these functions point towards a tumor suppressor 
role for CHK1, mouse models modulating ATR-CHK1 
expression and genetic evidence from human tumors 
suggest otherwise: Atr and Chk1 knock-out models do not 
display higher tumor frequency; Chk1 favors oncogene-
induced transformation in mice; CHK1 is frequently 
overexpressed in human cancers, while loss-of-function 
mutations are rare [2, 3]. Moreover, CHK1 affords 
protection against DNA damaging agents, a fact that 
prompted the use of CHK1 inhibitors as chemosensitizers 
[4]. Similarly, tumors whose oncogenic profile fuels 
RS were proposed to become addicted to ATR-CHK1 
response [1, 2]. In our recent study published in Oncogene 
[5], we hypothesized that T-cell acute lymphoblastic 
leukemia (T-ALL), an aggressive hematological cancer 
arising from T-cell precursor clonal expansion, could be 
one of such tumors and showed that CHK1 plays a key 
role in T-ALL cell maintenance. 
T-ALL cells tend to be highly proliferative 
due to a myriad of genetic lesions that culminate 
in cyclin-dependent kinase hyperactivation, and 
deregulated progression of S-phase that may impact 
on DNA replication [5, 6]. We found that T-ALL cells 
overexpressed CHK1 mRNA and protein as compared to 
normal hematopoietic progenitors. This was accompanied 
by aberrantly high CHK1 kinase activity, likely triggered 
by high basal levels of RS [5]. Experimental inactivation 
of CHK1, by a CHK1 selective inhibitor (PF-00477736) 
or by gene silencing, demonstrated that CHK1 is essential 
to control the accumulation of RS and to prevent apoptosis 
of T-ALL cells that appear to enter mitosis without having 
concluded DNA replication. Furthermore, accumulation 
of DNA damage in the context of CHK1 loss induced the 
activation of the ATM-CHK2 DNA double-strand break 
(DSB) response pathway, likely due to DSB formation 
upon the collapse of stalled replication forks. T-ALL 
apoptosis upon CHK1 inactivation was in the first instance 
dependent on ATM and caspase-3, since ATM inhibition 
prevented caspase-3 cleavage and rescued T-ALL cell 
viability despite sustained elevated amounts of RS 
markers [5]. 
Following the demonstration that T-ALL cells were 
eliminated using a CHK1 small molecule inhibitor as 
single agent, we showed that this effect was leukemia-
specific, since normal T-cell progenitors were not 
sensitive to the low doses of PF-00477736 that killed 
primary T-ALL patient cells. Moreover, the in vitro 
anti-leukemia effect of PF-00477736 was not prevented 
by microenvironment pro-survival factors, and the 
potential clinical value of CHK1 inhibition was further 
demonstrated by the fact that PF-00477736 limited the 
growth of xenografted T-ALL tumors [5]. Interestingly, 
our preliminary analyses indicated that T-ALL cells 
expressing higher CHK1 levels appeared more sensitive to 
CHK1 pharmacological inhibition, suggesting that CHK1 
expression could be a suitable drug response marker in 
T-ALL patients. As clinical trials against ATR-CHK1 
pathway may be envisaged, this issue warrants extended 
T-ALL patient analysis. 
T-ALL constitutes only a fraction of all ALL cases, 
but it associates with high-risk. Therapeutic options 
with less detrimental side-effects and/or effective upon 
relapse are most desired. Our findings defining CHK1 as 
a ‘subverted’ tumor suppressor that stands in T-ALL as a 
major guardian of leukemia cell survival, thereby formally 
acting as an oncogene, reinforce a new way of viewing 
the mechanisms of cancer progression [2] and may set the 
ground for anti-leukemia breakthrough approaches. In this 
context, it is important to understand the mechanisms of 
CHK1 upregulation in T-ALL. We thoroughly documented 
CHK1 transcript overexpression in primary T-ALL [5]. 
However, how this occurs remains undetermined. Maybe 
transcription factors known to activate CHK1, such 
as E2F (downstream of G1/S-phase CDK activity) or 
MYC (downstream of NOTCH1), are involved in CHK1 
overexpression in T-ALL. Or maybe as yet unidentified 
CHK1 regulatory elements are mutated or epigenetically 
altered. Curiously, in contrast to our findings, Chk1 
mRNA downregulation was documented in a murine 
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T-ALL model [7]. A more integrative view of the role of 
CHK1 in T-ALL is therefore required. We believe CHK1 
downregulation may occur at T-ALL initiation, driving 
genomic instability secondary to an increase in RS. As the 
pro-proliferative oncogenic program establishes and RS 
rises, leukemic cells are naturally selected for their ability 
to upregulate CHK1 as a means to maintain RS levels 
compatible with cell viability.
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